Immuneering’s (IMRX) Buy Rating Reiterated at Needham & Company LLC

by · The Cerbat Gem

Needham & Company LLC reaffirmed their buy rating on shares of Immuneering (NASDAQ:IMRX – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $11.00 price objective on the stock.

Several other equities analysts have also weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Wall Street Zen raised Immuneering from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Chardan Capital restated a “buy” rating and issued a $20.00 price target on shares of Immuneering in a report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Immuneering has a consensus rating of “Moderate Buy” and a consensus target price of $16.50.

Check Out Our Latest Analysis on Immuneering

Immuneering Stock Performance

IMRX opened at $5.65 on Monday. The company has a fifty day moving average price of $5.16 and a two-hundred day moving average price of $6.13. The firm has a market capitalization of $365.27 million, a PE ratio of -4.09 and a beta of 0.46. Immuneering has a 52 week low of $1.10 and a 52 week high of $10.08.

Immuneering (NASDAQ:IMRX – Get Free Report) last posted its quarterly earnings results on Friday, March 6th. The company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.13. Equities analysts forecast that Immuneering will post -1.86 EPS for the current year.

Insider Activity

In other news, Director Peter Feinberg bought 20,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were acquired at an average price of $4.35 per share, with a total value of $87,000.00. Following the transaction, the director owned 135,441 shares in the company, valued at $589,168.35. This represents a 17.32% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Thomas J. Schall bought 21,645 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was purchased at an average price of $4.67 per share, for a total transaction of $101,082.15. Following the purchase, the director directly owned 74,530 shares in the company, valued at approximately $348,055.10. This represents a 40.93% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders acquired a total of 51,819 shares of company stock worth $234,472 in the last three months. Company insiders own 22.90% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Sanofi bought a new position in Immuneering in the third quarter valued at $18,960,000. Empery Asset Management LP bought a new stake in Immuneering during the 4th quarter worth about $17,601,000. Vanguard Group Inc. boosted its stake in shares of Immuneering by 128.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,415,244 shares of the company’s stock worth $16,907,000 after buying an additional 1,358,322 shares during the last quarter. State Street Corp boosted its stake in shares of Immuneering by 1,289.7% during the 4th quarter. State Street Corp now owns 2,402,238 shares of the company’s stock worth $15,807,000 after buying an additional 2,229,374 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Immuneering by 10.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,993,958 shares of the company’s stock valued at $13,121,000 after acquiring an additional 195,176 shares in the last quarter. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

(Get Free Report)

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company’s lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

Read More